Back to News
Market Impact: 0.42
US FDA approves Lilly's breast cancer drug combo
Source: reuters.com
Healthcare & BiotechProduct LaunchesRegulation & Legislation
The FDA approved Eli Lilly's drug combination for adults with advanced breast cancer that has metastasized. The authorization expands Lilly's oncology treatment portfolio and creates a new commercial opportunity in metastatic breast cancer.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.72
Ticker Sentiment
LLY0.82
More News
- Eli Lilly Just Delivered Another Blowout Quarter. Is This Unstoppable Growth Stock Still a Buy?
- Apple's quarter is not perfect. But with enough to like, we raised our price target
- Jefferies upgrades Tempus AI stock rating to hold, raises price target to $70
- In one of the largest deals in tech history, Marvell buys Lumentum for $115B
- California’s Bay Area debates data centres ahead of US midterm elections
- Kimberly-Clark closes its acquisition of Tylenol maker Kenvue. What to expect next